Navigation Links
Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
Date:6/6/2008

an doubled.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on ALS, cancer, HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. Sangamo has established strategic partnerships with companies outside of the human therapeutic space including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to clinical trials of SB-509 and the potential for further study and development of SB-509, research and development of novel ZFP TFs and ZFNs and therapeutic applications of Sangamo's ZFP technology platform. Actual results may differ materially from these forward-looking statements due to a number of factors, including uncertainties relating to the initiation and completion o
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
2. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
3. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
4. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
5. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
6. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
7. Magellan Biosciences Companies to Feature Automated Products and New Tests for MRSA at the American Society for Microbiology Meeting, Booth 743
8. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
9. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
10. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
11. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/6/2008)...IPPENHAM, England, October 7 /PRNewswire-FirstCall... Index: 4565) and Vectura,Group plc ("Vectura"; LS...evaluating the efficacy, safety and tolerability o...uropean Respiratory Society (ERS) in Berlin,Germa...bromide), a novel,inhaled long-acting muscarinic a...
(Date:10/6/2008)... 6 /PRNewswire-USNewswire/ -- "A return to the use...opment is without scientific,justification," accor...rnatives to Laboratory Animals (ATLA). "An Assessm...earch" concludes that vaccine responses in,chimpan...d that claims of,chimpanzees, critical role and im...
(Date:10/6/2008)...video clips feature children, parents discussing c...ETHESDA, Md., Oct. 6 /PRNewswire-USNewswire/ -- Fr...rch in children saves lives and improves their,hea...al Institutes of,Health (NIH), "Children and Clini...es.nhlbi.nih.gov ), offers parents and health,care...
(Date:10/6/2008)...m Phase 3b Studies with Durezol Dosed Prior to Sur...Therapeutics, Inc., a,privately held ophthalmic-fo...hat Durezol(TM) (difluprednate ophthalmic emulsion...ich was approved by the U.S. Food and,Drug Adminis...icosteroid,indicated for the treatment of inflamma...
Breaking Medicine Technology:NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 2NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 3NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 4NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 5Research Attributes Lack of HIV/AIDS Vaccine to Use of Chimpanzees 2Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children 2Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children 3Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children 4Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 2Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 3Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 4Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 5Innovative Uses of Technology to Improve Health for Poor and Vulnerable People to be Explored at Rockefeller Foundation Conference 20872 1Innovative Uses of Technology to Improve Health for Poor and Vulnerable People to be Explored at Rockefeller Foundation Conference 20872 2Innovative Uses of Technology to Improve Health for Poor and Vulnerable People to be Explored at Rockefeller Foundation Conference 20872 3Innovative Uses of Technology to Improve Health for Poor and Vulnerable People to be Explored at Rockefeller Foundation Conference 20872 4Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation 5739 1Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation 5739 2Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation 5739 3Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation 5739 4Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation 5739 5OHSU Cancer Institute finds that drug stimulated immune system in prostate cancer 20869 1OHSU Cancer Institute finds that drug stimulated immune system in prostate cancer 20869 2OHSU Cancer Institute finds that drug stimulated immune system in prostate cancer 20869 3Latest Advances in Infection Prevention and Control to be Presented in Denver CO at Worlds Largest Annual Infection Prevention Conference June 15 19 20866 1
...rimary Endpoint of Improvement in Overall,Survival...rstCall/ --,Allos Therapeutics, Inc. today announc...otal Phase 3 study of Efaproxyn ,(efaproxiral) plu...th brain metastases originating from breast cancer... of demonstrating a,statistically significant impr...
...2007 /PRNewswire-FirstCall/ -- Anadys,Pharmaceutic...to,the discovery, development and commercializatio...s and cancer, announced today that it,has nominate...s an,orally-administered direct antiviral for the ...tion. , "We have identified a small-molecule, non-...
Other Medicine Technology:Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 2Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 3Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 4Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 5Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 6Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule,Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for,Clinical Development in Chronic Hepatitis C Virus Infection 2Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule,Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for,Clinical Development in Chronic Hepatitis C Virus Infection 3Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule,Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for,Clinical Development in Chronic Hepatitis C Virus Infection 4
(Date:10/6/2008)...de effects can affect length of stay, study says ,...Simple changes to hospital procedures can signific...e on opiates to relieve pain, a new study reveals.... 14 U.S. children,s hospitals, documented a 67 per...in relievers under these new procedures. , The...
(Date:10/6/2008)...ased resource designed to engage and educate viewe...ns including Health Savings Accounts (HSAs), Healt...ing Accounts (FSAs), has partnered with sister com...ices in concert with its existing direct-to-broker... MINNEAPOLIS (Business Wire EON) Oc...
(Date:10/6/2008)...eukemia Victim Ernie Davis, Is, Spokesperson for T...ght(R) Walk, WHI...s, a 1960s,football hero who was the first African...t of the new film from Universal Pictures, The Exp...ercame seemingly insurmountable,obstacles to becom...
(Date:10/6/2008)... Today, PARI Pharma GmbH will,unveil a prototype C...le,dose ampoules to control medication used in the...-dose ampoule that is required to operate the,nebu...ets an unmet need by,reducing the risk of using th...ying filling procedures, improving dose uniformity...
Breaking Medicine News(10 mins):Health News:Hospital Fixes Cut Opiate Errors in Kids 2Health News: LearnCDHC Bridges Education Gap on Consumer Directed Healthcare : Interactive Web resource engages and educates consumers about consumer-directed healthcare 2Health News: LearnCDHC Bridges Education Gap on Consumer Directed Healthcare : Interactive Web resource engages and educates consumers about consumer-directed healthcare 3Health News:Release of Universal Film The Express Draws Attention to Tragedy of Lives Cut Short by Blood Cancer 2Health News:PARI Pharma Unveils Closed System Using eFlow Technology at Medical Plastics Conference 2
...omen had about a 20 percent lower chance of develo... new research bolsters the theory that the female ...al cancer. Dr. Carlo La Vecchia, who led the s...uspected that estrogen in the pill could protect a...
...re is poorly controlled. Drugs and lifestyle modif...rtension) yet these measures are not being taken b...he Baylor School of Medicine, Houston, Texas, doct...00 adults over 25 and found that 27 per cent had h...
...anization for Scientific Research (NWO) discovered...tance to disease if they took extra zinc in additi..., zinc was largely ignored due to the difficulty i...Scientists now know that zinc deficiency leads to ...
...er these days, wonder premature memory loss is no... too much work causing lack of concentration, memo...erations in memory and neurotransmitters are found...nson's disease and Alzheimer's disease. // The fun...
Other Medicine News:
The IntraStent DoubleStrut Biliary Stent represents a completely new direction in stent design. The combination of parallel struts and unique cell geometry provide unparalleled performance.
The Smart Check Syphilis Device is a qualitative membrane device based immunoassay for the detection of TP (Treponema Pallidum) antibodies in whole blood/serum/plasma. For professional in vitro diagn
Bio-Quant, Inc. OneStep hCG InstaTest is an immunochromatographic assay designed for qualitative determination of human chorionic gonadotropin (hCG) in urine for early detection of pregnancy.
OneStep Midstream Urine hCG Pregnancy InstaTest is a test kit for the determination of hCG(Human Chorionic Gonadotropin) in urine specimens. This test kit is used to obtain a visual, qualitative resu
Medicine Products: